Xeris Pharmaceuticals | XERS - Debt



Xeris Pharmaceuticals reported $257.22M in Debt for its fiscal quarter ending in June of 2025.


Debt Change Date
Adcock Ingram Holdings ZAR 969.4M 688.86M Dec/2024
Celltrion KRW 2.22T 24.87B Mar/2025
Cspc Pharmaceutical CNY 507.33M 118.46M Dec/2024
Dianthus Therapeutics USD 1.33M 161K Jun/2025
Divis Laboratories Ltd 40M 40M Mar/2025
Eli Lilly USD 39.9B 1.39B Jun/2025
Kangmei Pharma CNY 221.82M 958.68M Mar/2025
Knight Therapeutics CAD 58.22M 109K Sep/2024
Laboratorios Farma EUR 129.3M 14.89M Jun/2025
Malin Corporation EUR 0 0 Dec/2024
Medical Developments International AUD 2.14M 144K Dec/2024
Neuren Pharmaceuticals AUD 0 0 Dec/2024
Organigram Holdings CAD 9.15M 35.6M Jun/2025
Pacira USD 580.49M 2.88M Jun/2025
Perrigo USD 3.65B 24.4M Jun/2025
Pharma Mar EUR 51.4M 405K Jun/2025
Qiagen NV USD 1.44B 35.7M Jun/2025
Sartorius EUR 4.66B 25.7M Jun/2025
Sino Biopharmaceutical CNY 9.71B 33.98M Dec/2024
Supernus Pharmaceuticals USD 31.77M 531K Jun/2025
Tilray USD 351.72M 15.26M Nov/2024
Zz Pientze Pharmaceu 1.12B 70.31M Mar/2025